What is the hydrocortisone equivalent dose for a daily 30 mg dose of deflazacort?

Deflazacort 30mg Hydrocortisone Equivalent Dose

Deflazacort 30 mg daily is approximately equivalent to 20-21 mg of hydrocortisone based on established glucocorticoid potency ratios.

Calculation and Rationale

The conversion is based on the relative glucocorticoid potency between deflazacort and hydrocortisone:

• Standard equipotency ratio: Deflazacort to prednisolone is approximately 1.4:1 (mg:mg) 1, 2
• Prednisolone to hydrocortisone: The established ratio is 1:4 (meaning 5 mg prednisolone = 20 mg hydrocortisone) 3

Step-by-step conversion:

1. Convert deflazacort 30 mg to prednisolone equivalent: 30 mg ÷ 1.4 = 21.4 mg prednisolone
2. Convert prednisolone to hydrocortisone: 21.4 mg ÷ 5 × 20 = ~85 mg hydrocortisone

However, this calculation appears incorrect based on clinical context.

Corrected Clinical Interpretation

Using the more clinically relevant direct comparison:

• Research demonstrates deflazacort has variable equipotency ratios depending on the pharmacodynamic endpoint measured 2
• For anti-inflammatory effects (most relevant clinically): the ratio ranges from 1.14 to 1.54 (deflazacort:prednisolone) 1, 2
• Using the conservative ratio of 1.5:1: 30 mg deflazacort ≈ 20 mg prednisolone
• Converting to hydrocortisone: 20 mg prednisolone = 80 mg hydrocortisone 3

Therefore, deflazacort 30 mg ≈ 20 mg prednisolone ≈ 80 mg hydrocortisone

Important Clinical Caveats

Pharmacokinetic Differences

• Deflazacort has a significantly shorter half-life (1.3 hours for its active metabolite 21-desacetyldeflazacort) compared to prednisolone 4
• This results in shorter duration of pharmacodynamic effects, meaning the clinical impact may not be fully equivalent despite similar peak potency 4

Context-Dependent Potency

The equipotency ratio varies based on which endpoint you measure 2:

• Cortisol suppression: 2.27:1 ratio
• Osteocalcin suppression: 1.54:1 ratio
• Eosinophil suppression: 1.14:1 ratio
• Lymphocyte suppression: 2.77:1 ratio

This variability means deflazacort may provide less HPA axis suppression at equivalent anti-inflammatory doses, which could be advantageous or disadvantageous depending on clinical goals.

Practical Application

• For adrenal insufficiency replacement: Standard maintenance is 15-25 mg hydrocortisone daily 5
• Deflazacort 30 mg would represent supraphysiologic dosing if used for replacement therapy
• The FDA-approved dose for DMD is 0.9 mg/kg/day 6, which in a 70 kg adult = 63 mg daily (far exceeding physiologic replacement)

Warning About Direct Substitution

Do not directly substitute deflazacort for hydrocortisone in adrenal insufficiency management without endocrine consultation, as:

• Deflazacort has no mineralocorticoid activity (unlike hydrocortisone) 5
• The shorter half-life may not provide adequate 24-hour coverage 4
• Deflazacort is not recommended for physiologic glucocorticoid replacement 5